Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.

@article{Nicolau2009DifferencesAL,
  title={Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.},
  author={Jos{\'e} Carlos Nicolau and Marc C. Cohen and Gilles Montalescot},
  journal={Journal of cardiovascular pharmacology},
  year={2009},
  volume={53 6},
  pages={440-5}
}
Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic agents for the treatment of patients with acute coronary syndromes (ACS). In patients with unstable angina and non-ST segment elevation myocardial infarction (MI), many data support the use of the LMWH enoxaparin to reduce cardiovascular events and death. LMWHs also appear more effective than unfractionated heparin in reducing the composite end point of acute… CONTINUE READING

Similar Papers

Loading similar papers…